Research Paper Volume 12, Issue 4 pp 3312—3339
Analysis of immune-related signatures of lung adenocarcinoma identified two distinct subtypes: implications for immune checkpoint blockade therapy
Figure 5. Functional annotation in high-/low-risk subtypes of LUAD. (A) Dysregulation of signaling pathways stratified by identified LUAD subtypes. (B) Expression profiles of cell cycle checkpoint markers in the high-risk group versus low-risk group.